"Anosmia" the mysterious collateral damage of COVID-19.
J Neurovirol
; 28(2): 189-200, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1729426
ABSTRACT
COVID-19 pandemic spreads worldwide, with more than 100 million positive cases and more than 2 million deaths. From the beginning of the COVID-19 pandemic, several otolaryngologists described many cases of a sudden loss of smell (anosmia) associated with the disease with or without additional symptoms. Anosmia is often the first and sometimes the only sign in the asymptomatic carriers of COVID-19. Still, this disorder is underestimated, and it is not life-threatening. However, it significantly decreases the quality of life. This olfactory dysfunction continues in several cases even after the nasopharyngeal swab was negative. The occurrence of anosmia can be used as a screening tool for COVID-19 patients and can be used to identify these patients to accomplish the isolation and tracking procedures. In this review, we highlighted the possible mechanisms of anosmia in COVID-19 patients, major pathologies and features of anosmia, implications of anosmia in early diagnosis of COVID-19, evaluation of the smell function during COVID-19, and management and treatment options of COVID-19 anosmia.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Olfaction Disorders
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
J Neurovirol
Journal subject:
Neurology
/
Virology
Year:
2022
Document Type:
Article
Affiliation country:
S13365-022-01060-9
Similar
MEDLINE
...
LILACS
LIS